Breaking the DNA damage response to improve cervical cancer treatment
- 1 January 2016
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 42, 30-40
Abstract
No abstract availableKeywords
Funding Information
- Dutch Cancer Society (RUG/NKB 2010-4833)
- The Netherlands Organization for Scientific Research (NWO-VIDI 016.136.334)
- University of Groningen
This publication has 137 references indexed in Scilit:
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancerBreast Cancer Research and Treatment, 2012
- Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiationCell Death & Disease, 2012
- The role of ATM and 53BP1 as predictive markers in cervical cancerInternational Journal of Cancer, 2012
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell linesBritish Journal of Cancer, 2011
- The ATR barrier to replication-born DNA damageDNA Repair, 2010
- A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trialInvestigational New Drugs, 2010
- DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA StabilizationMolecular Cell, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis updateInternational Journal of Cancer, 2007
- p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA DamageCancer Cell, 2007